There is a shifting trend in the analytical platform from immunoassay to mass spectrometry in clinical research and diagnostic lab in the past decade. This growing trend of mass spectrometry application in clinical lab is due to the superior selectivity and sensitivity of mass spectrometers. More importantly, mass spectrometry can analyse multiple compounds in a single analysis using much lesser sample amount compared to immunoassay. The application of mass spectrometry in various clinical analysis using Shimadzu’s Ultra Fast Mass Spectrometry (UFMS) Technology will be discussed in this webinar. Lastly, Shimadzu latest innovative technology in clinical automation and rapid screening will also be highlighted.
Daryl Hee (Ph.D.)
Senior Product Specialist (LCMS)
Shimadzu (Asia Pacific) Pte Ltd
Daryl Hee is currently the Senior Product Specialist for LCMS at Shimadzu (Asia Pacific) Pte Ltd. He completed his PhD study at the National University of Singapore (NUS) in 2010. Following that, he continued his postdoctoral research at the Department of Medicine NUS in clinical trial pharmacokinetics studies and conducted lectures on drug and metabolite analysis using LCMS. He is currently also holding the Adjunct Senior Research Fellow position with NUS medicine Department.